The Medical Letter on Drugs and Therapeutics
Ranibizumab (Lucentis) for Macular Degeneration
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ranibizumab (Lucentis – Genentech) as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). Ranibizumab is closely related to bevacizumab (Avastin), which is FDA-approved for intravenous treatment of metastatic colorectal cancer and non-small cell lung cancer,1 but has also been used off-label for intravitreal treatment of neovascular AMD.

THE DISEASE — AMD occurs in two forms, dry (atrophic) and wet (neovascular, exudative). About 90% of patients with early AMD have the dry form. Wet AMD is more common in those with advanced disease. Dry AMD may produce a slow deterioration of central vision. Wet AMD can cause rapid distortion and loss of central vision. Most patients with AMD who have lost vision to the level of legal blindness (best corrected visual acuity of 20/200 or worse in the better- seeing eye) have ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ranibizumab (Lucentis) for Macular Degeneration
Article code: 1246a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian